
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
The financial outlook for DexCom appears positive due to several key momentum drivers, including anticipated Medicare expansion and additional coverage wins that are expected to enhance the number of covered lives significantly. The company's recent innovations, such as the G7 15-day continuous glucose monitoring system and an improved adhesive patch, are likely to stimulate demand and drive revenue growth, alongside an expected robust increase in earnings per share. Furthermore, operational efficiency improvements and sales force productivity are projected to support DexCom's objectives of achieving mid-teens revenue growth and over 20% EPS growth through 2028.
Bears say
DexCom reported sensor revenue of $1.18 billion for the year, indicating a year-over-year growth of 20%, but the hardware revenue of $34 million saw a significant decline of 31% year-over-year. The company's fiscal year 2026 revenue guidance of $5.16 billion to $5.25 billion is slightly below consensus expectations and reflects anticipated deceleration in 4Q US sales, attributed to shifting seasonality and a growing reliance on pharmacy distribution. Furthermore, with the company's recent history of decelerating growth and execution challenges, there are concerns that DexCom shares may continue to trade at a discount compared to competitors, suggesting a prolonged negative outlook.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares